355 related articles for article (PubMed ID: 35789689)
1. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
Shu Y; He X; Liu Y; Wu P; Zhang Q
Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
[TBL] [Abstract][Full Text] [Related]
2. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.
Liu M; Gu L; Zhang Y; Zhou H; Wang Y; Xu ZX
Front Pharmacol; 2024; 15():1290975. PubMed ID: 38357304
[No Abstract] [Full Text] [Related]
3. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
4. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
Yun X; Zhou Y; Wu D; Liu Y; Wu Q
Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
Zhu Z; Liu M; Zhang H; Zheng H; Li J
Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
[TBL] [Abstract][Full Text] [Related]
6. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
8. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
[No Abstract] [Full Text] [Related]
9. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Cui Z; Cheng F; Wang L; Zou F; Pan R; Tian Y; Zhang X; She J; Zhang Y; Yang X
Front Pharmacol; 2023; 14():1259908. PubMed ID: 37954852
[No Abstract] [Full Text] [Related]
10. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax.
Yang Y; Shu Y; Chen G; Yin Y; Li F; Li J
PLoS One; 2022; 17(12):e0278725. PubMed ID: 36477747
[TBL] [Abstract][Full Text] [Related]
11. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
13. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin.
Xu Z; Huang D; Liu Q; Liu S; Liu J; Wang H; Shen Z
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38695550
[TBL] [Abstract][Full Text] [Related]
14. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
Wen H; Lu C; Zhang M; Qi X
Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
[TBL] [Abstract][Full Text] [Related]
15. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
16. Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.
Yuan T; Li F; Hou Y; Guo H
Front Pharmacol; 2023; 14():1266890. PubMed ID: 38074150
[No Abstract] [Full Text] [Related]
17. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system.
Chang E; Shi YF; Liu JF; Wei W
Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38700323
[TBL] [Abstract][Full Text] [Related]
19. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
[TBL] [Abstract][Full Text] [Related]
20. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
[Next] [New Search]
